NCT06188208
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06188208
Title A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vividion Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP | AUS

Facility Status City State Zip Country Details
California Research Institute Los Angeles California 90027 United States Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
NEXT Austin Austin Texas 78758 United States Details
MDACC Houston Texas 77030 United States Details
NEXT Dallas Irving Texas 75039 United States Details
NEXT San Antonio San Antonio Texas 78299 United States Details
University of Utah Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
NEXT Virginia Fairfax Virginia 22031 United States Details
Blacktown Hospital Blacktown New South Wales Australia Details
Orange Health Service Orange New South Wales Australia Details
Gold Coast University Hospital Southport Queensland Australia Details
Cancer Research South Australia Adelaide Australia Details
ICON Cancer Research South Brisbane Australia Details
START Barcelona Hospital HM Nou Delfos Barcelona Spain Details
Vall d'Hebron Barcelona Spain Details
Hospital Universitario 12 de Octubre Madrid Spain Details
NEXT Madrid Madrid Spain Details
START Madrid CIOCC Madrid Spain Details
Start Madrid-FJD, Hospital Fundacion Jimenez Diaz Madrid Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field